Francesco Sparano1, Michele Cavo2, Pasquale Niscola3, Tommaso Caravita3, Fabio Efficace4. 1. Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Via Benevento, 6, 00161, Rome, Italy. 2. Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S.Orsola-Malpighi" University Hospital, University of Bologna, Bologna, Italy. 3. Hematology Unit, S Eugenio Hospital, Rome, Italy. 4. Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Via Benevento, 6, 00161, Rome, Italy. f.efficace@gimema.it.
Abstract
PURPOSE: We performed a systematic review to quantify the amount of evidence-based data available on patient-reported outcomes (PRO) in Relapsed/Refractory Multiple Myeloma (RRMM) patients and to examine the added value of such studies in supporting clinical decision-making. METHODS: We conducted a search in PubMed/Medline and the Cochrane Library to identify studies published between January 1990 and May 2017. All studies, regardless of the design, including patients with RRMM and also evaluating PRO were considered. For each study, we collected both PRO and traditional clinical outcomes, such as survival and toxicity information, based on a predefined data extraction form. RESULTS: After having screened 1680 records, 11 studies were identified and these included six randomized controlled trials (RCT). Overall, there were five studies focusing on proteasome inhibitors (PIs), four on immunomodulatory drugs (IMiDs), one on both PIs and IMiDs, and one on monoclonal antibodies. Considering only RCTs, it was found that primary clinical efficacy endpoints frequently favored experimental arms, while (physician-reported) toxicity data did not. However, inspection of PRO data revealed novel information that often contrasted with standard toxicity, for example, by not indicating worse quality of life outcomes or symptom severity for patients enrolled in the experimental arms. CONCLUSIONS: There is paucity of evidence-based data regarding the impact of therapies on quality of life and symptom burden of patients with RRMM. Inclusion of PRO in future studies of patients with RRMM is needed to better inform clinical decision-making.
PURPOSE: We performed a systematic review to quantify the amount of evidence-based data available on patient-reported outcomes (PRO) in Relapsed/Refractory Multiple Myeloma (RRMM) patients and to examine the added value of such studies in supporting clinical decision-making. METHODS: We conducted a search in PubMed/Medline and the Cochrane Library to identify studies published between January 1990 and May 2017. All studies, regardless of the design, including patients with RRMM and also evaluating PRO were considered. For each study, we collected both PRO and traditional clinical outcomes, such as survival and toxicity information, based on a predefined data extraction form. RESULTS: After having screened 1680 records, 11 studies were identified and these included six randomized controlled trials (RCT). Overall, there were five studies focusing on proteasome inhibitors (PIs), four on immunomodulatory drugs (IMiDs), one on both PIs and IMiDs, and one on monoclonal antibodies. Considering only RCTs, it was found that primary clinical efficacy endpoints frequently favored experimental arms, while (physician-reported) toxicity data did not. However, inspection of PRO data revealed novel information that often contrasted with standard toxicity, for example, by not indicating worse quality of life outcomes or symptom severity for patients enrolled in the experimental arms. CONCLUSIONS: There is paucity of evidence-based data regarding the impact of therapies on quality of life and symptom burden of patients with RRMM. Inclusion of PRO in future studies of patients with RRMM is needed to better inform clinical decision-making.
Authors: Anders Waage; Peter Gimsing; Gunnar Juliusson; Ingemar Turesson; Nina Gulbrandsen; Tommy Eriksson; Martin Hjorth; Johan Lanng Nielsen; Stig Lenhoff; Jan Westin; Finn Wislöff Journal: Br J Haematol Date: 2004-04 Impact factor: 6.998
Authors: Andra Morrison; Julie Polisena; Don Husereau; Kristen Moulton; Michelle Clark; Michelle Fiander; Monika Mierzwinski-Urban; Tammy Clifford; Brian Hutton; Danielle Rabb Journal: Int J Technol Assess Health Care Date: 2012-04 Impact factor: 2.188
Authors: Katja Weisel; Meletios Dimopoulos; Kevin W Song; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Craig J Gibson; Mohamed Zaki; Christian Jacques; Jesus San Miguel Journal: Clin Lymphoma Myeloma Leuk Date: 2015-06-06
Authors: Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos Journal: Lancet Oncol Date: 2013-09-03 Impact factor: 41.316
Authors: Sara Bringhen; Maria Victoria Mateos; Sonja Zweegman; Alessandra Larocca; Antonietta Pia Falcone; Albert Oriol; Davide Rossi; Maide Cavalli; Pierre Wijermans; Roberto Ria; Massimo Offidani; Juan Jose Lahuerta; Anna Marina Liberati; Roberto Mina; Vincenzo Callea; Martijn Schaafsma; Chiara Cerrato; Roberto Marasca; Luca Franceschini; Andrea Evangelista; Ana-Isabel Teruel; Bronno van der Holt; Vittorio Montefusco; Giovannino Ciccone; Mario Boccadoro; Jesus San Miguel; Pieter Sonneveld; Antonio Palumbo Journal: Haematologica Date: 2013-02-26 Impact factor: 9.941
Authors: Karin Jordan; Irina Proskorovsky; Philip Lewis; Jack Ishak; Krista Payne; Noreen Lordan; Charalampia Kyriakou; Cathy D Williams; Sarah Peters; Faith E Davies Journal: Support Care Cancer Date: 2014-02 Impact factor: 3.603
Authors: P Sonneveld; S G Verelst; P Lewis; V Gray-Schopfer; A Hutchings; A Nixon; M T Petrucci Journal: Leukemia Date: 2013-06-20 Impact factor: 11.528
Authors: Xin Shelley Wang; Qiuling Shi; Tito R Mendoza; Araceli Garcia-Gonzalez; Ting-Yu Chen; Mona Kamal; Tsun Hsuan Chen; Cobi Heijnen; Robert Z Orlowski; Charles S Cleeland Journal: Support Care Cancer Date: 2021-04-01 Impact factor: 3.603
Authors: Fabio Efficace; Mario Boccadoro; Antonio Palumbo; Maria Teresa Petrucci; Francesco Cottone; Laura Cannella; Elena Zamagni; Pasquale Niscola; Charalampia Kyriakou; Tommaso Caravita; Massimo Offidani; Franco Mandelli; Michele Cavo Journal: Health Qual Life Outcomes Date: 2018-06-18 Impact factor: 3.186
Authors: Evangelos Terpos; Joseph Mikhael; Roman Hajek; Ajai Chari; Sonja Zweegman; Hans C Lee; María-Victoria Mateos; Alessandra Larocca; Karthik Ramasamy; Martin Kaiser; Gordon Cook; Katja C Weisel; Caitlin L Costello; Jennifer Elliott; Antonio Palumbo; Saad Z Usmani Journal: Blood Cancer J Date: 2021-02-18 Impact factor: 11.037
Authors: Mona Kamal; Xin Shelley Wang; Qiuling Shi; Teresa M Zyczynski; Catherine Davis; Loretta A Williams; Hui-Kai Lin; Araceli Garcia-Gonzalez; Charles S Cleeland; Robert Orlowski Journal: Support Care Cancer Date: 2020-05-11 Impact factor: 3.603
Authors: Ajai Chari; Dorothy Romanus; Pronabesh DasMahapatra; Michael Hoole; Maria Lowe; Chris Curran; Scott Campbell; Jill A Bell Journal: Oncologist Date: 2019-08-01